Realigning the Hub
A pharmaceutical company offering a hub designed to address patient medication access challenges received customer feedback expressing dissatisfaction from both patients and providers.
Lining up support for a New Technology Add-on Payment in a rare-disease treatment
A biopharma company wanted to know the likelihood of receiving an NTAP after launching an inpatient treatment.
FY24 Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital Prospective Payment System (LTCH) Proposed Rule
Download to see features of the proposed rule.
Using published evidence and compendia to support expanded coverage for an off-label medication dosage
A pharma company needed to evaluate the likelihood that drug compendia would positively rate an off-label dosage of an FDA-approved medication to support additional payer coverage.
Pricing an oral formulation for a bioequivalent COPD product
A biopharma company needed an appropriate pricing model for a new tablet formulation of a successful existing infusion.
Developing strategic game plans in response to shifts in federal policy
Biopharmaceutical companies engaged Magnolia to help them understand the implications of the Inflation Reduction Act of 2022 and develop long-term strategic plans to adjust for the sweeping market changes it will cause.
Launch planning in an ever-evolving policy and regulatory landscape
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies
Developing the appropriate regulatory strategy for a patient-centric, therapy-agnostic app
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease
Using payer and age mix as the basis for developing a go-to-market strategy for a prelaunch drug
A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics
Providing program management support in the lead-up to NDA submission and launch
A development-stage biopharma company engaged Magnolia to help put in place an overarching launch road map for a drug that had just received positive phase 3 data